Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 7.63B -34.4% |
| Revenue (ttm) | 246.16M |
| Net Income | -308.20M |
| EPS | -1.59 |
| Shares Out | 195.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,223,900 |
| Open | 38.60 |
| Previous Close | 37.68 |
| Day's Range | 37.42 - 39.88 |
| 52-Week Range | 33.66 - 97.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 105.85 (+170.86%) |
| Est. Earnings | Dec 1, 2026 |
About Nanjing Leads Biolabs
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity. In addition, it develops LeadsBody platform,... [Read more]
Analyst Summary
According to 6 analysts, the average rating for 9887 stock is "Strong Buy." The 12-month stock price target is $105.85, which is an increase of 170.86% from the latest price.
News
Leads Biolabs Doses First Patient In Phase 1b/2 Opamtistomig Trial In Colorectal Cancer
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK) said Friday it dosed the first patient in an open-label, multicenter Phase 1b/2 trial evaluating Opamtistomig, or LBL-024, in combination therapy ...
FDA Grants Fast Track Tag To Leads Biolabs' Opamtistomig In Biliary Tract Cancer
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to opamtistomig (LBL-024), its investigational antib...
Nanjing Leads Biolabs To Present Opamtistomig Phase IIb Study At ESMO 2026
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK), a clinical-stage biotechnology company announced that its pivotal registrational Phase IIb study of opamtistomig (LBL-024), as monotherapy for pa...
Nanjing Leads Biolabs Earnings release: H1 2026
Nanjing Leads Biolabs released its H1 2026 earnings on August 31, 2026, summarizing the period's financial results.
Nanjing Leads Biolabs Quarterly report: H1 2026
Nanjing Leads Biolabs has published its H1 2026 quarterly earnings report on August 31, 2026.
Nanjing Leads Biolabs Slides: H1 2026
Nanjing Leads Biolabs has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 31, 2026.
Nanjing Leads Biolabs Earnings Call Transcript: H2 2025
2025 revenue was CNY 177m, with higher R&D spending and a narrower pre-tax loss; cash reserves reached CNY 1.548bn. The key 2026 milestone is an LBL-024 BLA submission targeted for Q3, alongside expanded clinical and BD activity.
Nanjing Leads Biolabs Annual report: H2 2025
Nanjing Leads Biolabs has published its H2 2025 annual report on March 27, 2026.
Nanjing Leads Biolabs Earnings release: H2 2025
Nanjing Leads Biolabs released its H2 2025 earnings on March 27, 2026, summarizing the period's financial results.
Nanjing Leads Biolabs Slides: H2 2025
Nanjing Leads Biolabs has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 27, 2026.